The invention relates to a method for facilitating endosperm development in an angiosperm central cell in absence of karyogamy, or fertilization by a sperm cell. The method according to the invention comprises specifically and selectively inhibiting, or substantially decreasing expression or activity, or lowering the concentration, of RBR1 in the central cell, by cell specific expression of an agent targeting either the expression of the gene encoding RBR1, or by directly or indirectly targeting RBR1 protein through cell-specific expression of an agent leading to degradation of the protein. The invention further relates to a recombinant angiosperm cell having the potential for endosperm development from a central cell in absence of fertilization. A related aspect encompasses a plant comprising such cell, and seed derived therefrom in absence of fertilization.
The invention relates to a computer-implemented method for determining a sleep restoration index indicative of a change of slope of slow waves during a non-REM sleep phase. The method employs a first neural networks for determining and filtering out epileptic spikes in the EEG data and a second neural network for identifying and labeling sleep stages. Combining the information generated by these networks, slow waves are identified and a change of slope of the slow waves is determined. The invention also relates to an EEG system and a computer program configured to executes the method.
A monitoring device for monitoring oxygenation of tissue (31) comprises a near-infrared optical detection unit (100) and a probe unit (40) having a plurality of light emitters (50) directed toward the tissue (31), and at least one light detector (10) receiving light returning from the tissue (31). The probe unit (10) comprises a rigid support structure (1) that carries the plurality of light emitters (50) and/or the at least one light detector (10). The rigid support structure (1) comprises a plurality of positioning sensors (5) for detecting a positioning of the probe unit (10) relative to a tissue surface (30) located above the tissue (31) and several sensor guide elements (3) extending from the support structure (1) and moveably supporting the plurality of positioning sensors (50). The probe unit (10) further comprises a cushion structure (2) that comprises an attachment side (20) attached to the support structure (1) and a contacting side (21), opposite to the attachment side (20), having a compressible surface (22) for contacting the tissue surface (30). The plurality of positioning sensors (5) moveably extend through the cushion structure (2) towards the contacting side (21) of the cushion structure (2).
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
4.
DESIGNED ANKYRIN REPEAT PROTEIN AGENTS TARGETING BRACHYURY AND THEIR USE IN TREATMENT OF CHORDOMA
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Ex vivo tissue culturing and sampling system (2) comprising a microfluidic cartridge (4) and a microfluidic sampling apparatus (3) that receives the microfluidic cartridge and a tissue support substrate (5) on which a tissue sample (1) to be cultured and analysed is mounted, the tissue support substrate separable from the microfluidic cartridge and comprising a porous hydrophilic membrane (19), the microfluidic cartridge comprising - a body (10), - a reaction chamber (20) formed within the body and configured to be sealingly closed by a seal (24) around the tissue sample (1) on the tissue support substrate (5), and - a transparent observation window (16) bounding one side of the reaction chamber configured to allow microscope imaging of the tissue sample, the microfluidic sampling apparatus comprising - a cartridge holder (6) in which the microfluidic cartridge and biological sample support substrate is removably mounted, - a reagent fluid flow system (7) configured to pump liquid through the microfluidic cartridge reaction chamber, and - a gas to liquid diffusion device (8) connected to the reagent fluid flow system upstream of the microfluidic cartridge reaction chamber.
The invention relates to a CjCas9 variant characterized by at least one of the mutations E789K and S951G. The invention further relates to base editing enzymes comprising the Cas variant according to the invention and an adenosine deaminase activity, and to polynucleotides encoding same.
A system and method are provided for visually conveying a physiological state of a patient. For that purpose, a graphical representation of a patient may be established on a display. The graphical representation may be configured to visually convey a current state of the physiological parameter using a set of graphical elements. To further visually convey a future state of the physiological parameter using the graphical representation of the patient, a prediction technique may be used to obtain at least one predicted value of the physiological parameter for at least one future time instance and a modified version of a set of graphical elements may be selected for display based on a predicted value of the physiological parameter. The modified version may be modified by a visual attribute of the set of graphical elements having been modified. For example, a rendering style may be modified. This way, a viewer will recognize a visualized future state in the same manner as that the viewer would recognize a visualized current state, while still being able to distinguish the visualization of the future state from that of the current state.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
8.
IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF
The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (Spain)
Inventor
Margarit Taule, Josep Maria
Liu, Shih-Chii
Jimenez Jorquera, Cecilia
Abstract
A neurocomputational electrochemical sensing device (1) is proposed for predicting properties of a substance. The device (1) comprises: a plurality of electrochemical sensors constituting a sensor array (3), the sensors being sensitive to sensed attributes advantageous to predict a set of properties of interest of the substance, each sensor being configured to output a sensor output signal indicative of a sensor response of the respective sensor to measurable changes in the sensed attributes of the substance; a readout circuit (5) for biasing the sensors and for conditioning the sensor output signals into readout circuit output signals to facilitate further processing of the sensor responses; and an artificial neural network processor (7) for processing the readout circuit output signals, the processor (7) comprising neurons interconnected by synapses, the processor (7) being configured to output a set of processor output signals whose signal values are indicative of the properties to predict. The sensor array (3) comprises first electrochemical sensors selective to properties correlated with the desired properties to predict, and second electrochemical sensors sensitive primarily to the main interferents of the substance. The neurons and/or the synapses are configured to be trained to compensate for sensor drift and/or cross-sensitivities upon generating the processor output signals.
The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16 (I) and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.
The invention relates to a method for identifying and quantifying a polypeptide from a library of polypeptides. The method comprises the steps of: 1—providing a polypeptide library and a detection tag library, 2—generating a nested library comprising the polypeptides and the detection tags, 3—sequencing the nested library, 4—selecting a member of the nested library in one or several selection steps that are independent of a physical genotype-phenotype linkage, 5—isolating the detection tag from the selected polypeptide, 6—identifying and quantifying the detection tag by mass spectrometry, 7—obtaining the sequence of the selected polypeptide. The invention also relates to a collection of polypeptides, a collection of detection tags, and a collection of plasmid vectors.
The disclosure relates to the field of multiple sclerosis (MS) stratification by analyzing the body fluid of an MS patient. The invention also relates to the field of antigen specific immunotherapies, such as the induction of tolerance.
Index creation in a streaming database with medical state parameters allows near-real-time access to medical state parameters reflecting medical states of patients. A message broker receives messages that include records with current measured medical state parameter values of patients. A stream processor processes messages with a plurality of parameter augmentation algorithms to derive additional computed medical state parameter values for a respective patient. Records with the computed values are inserted via generated messages into any incoming data stream. A data handler can create persisted patient-signal specific stream data tables for unknown combinations of patient identifier and signal identifier in the streaming database, and can create a block range index for the time information of the persisted stream data table. Records contained in the received and generated messages are written into respective persisted patient-signal specific stream data tables of the streaming database, and respective block range indexes are updated accordingly.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
The invention relates to immunopeptidome-derived bacterial peptides (IPdBPs), microbe-derived peptides capable of stimulating tumour-associated lymphocytes and eliciting an anti-tumour immune response. The invention further discloses T cell receptors capable of recognizing such peptides in the context of patient HLA. The invention further relates to the use of the peptides and TCRs in treatment of tumour patients.
The invention provides a method of predicting the prognosis of a breast cancer patient by determining the expression level of p53 and GATA in a lymph node metastasis sample. The invention further encompasses pharmaceutical compositions, or methods of treating patients with a good or poor prognosis identified using the above methods, in addition to a kit, or system comprising the means to determine an expression level of p53 and/or GATA3 in a lymph node metastasis sample.
The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.
The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.
In particular, the present invention relates to a cyclic peptide, wherein said cyclic peptide comprises an amino acid sequence (1), wherein said amino acid sequence (I) comprises the following amino acid sequence: X1-X2-X3-C4-X5-X6-X7-C8-X9-X10-X11-P12-I13-T14-NIS-D16-Q17-K18-K19-L20-C21-X22-X23-X24-C25-X26-X27-X28-X29-X30 (SEQ ID NO: 1), wherein
X1, X2, X3, X5, X6, X7, X9, X10, X11, X22, X23, X24, X26, X27, X28 and X29 are independently of each other an amino acid; C4, C8, C21 and C25 are independently of each other cysteine; P12 is proline; I13 is isoleucine; T14 is threonine; N15 is asparagine; D16 is aspartic acid; Q17 is glutamine; K18 and K19 are independently of each other lysine; L20 is leucine; and X30 is an amino acid or a deletion,
wherein said cysteines C4 and C25 form a first disulfide bond and said cysteines C8 and C21 form a second disulfide bond.
Computer system and computer-implemented method for rendering representations of blood gas state parameters of a patient to support a medically trained person in blood gas analysis of the patient's blood, comprising: receiving, from a data source, time series of sampled measurement values obtained from a plurality of blood gas analysis sensors for the following blood gas state parameters of the patient: Glucose, Chloride, Potassium, Calcium, Sodium, and Hemoglobin; mapping each state parameter to a predefined corresponding graphical representation with each graphical representation for a particular state parameter being distinct from all graphical representations of the remaining state parameters; and rendering, in a virtual 3D tunnel shaped scene representing the inside of an artery, animated visualizations of the graphical representations, in accordance with predefined animation rules, such that respective graphical objects move through the inside of the artery and reflect current values of the respective state parameters.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary products; dietetic substances
and foodstuffs for medical or veterinary use, food for
babies; dietary supplements for humans and animals; herbal
supplements; homogenized food for medical use;
pharmaceutical preparations in the form of tablets,
capsules, sachets, drinkable solutions or suspensions;
parenteral preparations; fats, oils and emulsions for
medical use; biological and chemical reagents for medical or
veterinary use; anti-inflammatories. Infusion sets; intravenous feeding tubes; intravenous
feeding bottles; intravenous catheters. Provision of information on dietary supplements and
nutrition; dietary and nutrition recommendation services,
particularly with regard to parenteral nutrition; services
provided by consultants in the medical, medicinal and
pharmaceutical field; provision of information in the
pharmaceutical field; medical services.
19.
A COMPUTER-IMPLEMENTED METHOD, DEVICE, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR PROCESSING ANATOMIC IMAGING DATA
A computer-implemented method for processing anatomic imaging data, the method comprising, for a plurality of anatomic specimens: acquiring 3D imaging data of a specific body part of an anatomic specimen of the plurality of anatomic specimens; acquiring 2D images of the specific body part of the anatomic specimen from a plurality of different perspectives with respect to the specific body part; determining a plurality of camera matrices P corresponding to the acquired 2D images; generating synthetic 2D images by projecting the acquired 3D imaging data in accordance with the plurality of camera matrices P; and associating the acquired 2D images with one of the synthetic 2D images as training data pairs in accordance with the plurality of camera matrices P and plurality of perspectives. The method further comprising generating a training dataset for use in training an artificial intelligence algorithm using the training data pairs.
The present invention is directed to a method for introducing charged compounds into three-dimensional biological tissues comprising the step of introducing at least one charged compound of interest into the biological tissue, wherein a composition for dissolving and removing lipids and/or a composition for introducing at least one charged compound of interest into the bio- logical tissue is injected into the biological tissue and a pulsed electrical field (PEF) is applied to the biological tissue. The invention further relates to a device for use in this method, and a use of this method or this device for histological staining.
The invention relates to a dye molecule described by a general formula (I) or (I-A), wherein R1and R2, R3, R4, R5, R6πππ-electron system of formula (I) by a double bond.
C09B 23/06 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups three CH groups, e.g. carbocyanines
C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
22.
METHODS OF TUMOUR THERAPY WITH A COMBINATION MEDICAMENT COMPRISING IL-12 AND AN AGENT FOR BLOCKADE OF T-CELL INHIBITORY MOLECULES
The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist blockade of T-cell inhibitory molecules, including non-agonist LAG-3 ligand, non-agonist TIM-3 ligand, non-agonist BLTA ligand, non-agonist TIGIT ligand, non-agonist VISTA ligand, non-agonist B7/H3 ligand, non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Basilea Pharmaceutica International AG, Allschwil (Switzerland)
UNIVERSITÄT ZÜRICH (Switzerland)
Inventor
Obrecht, Daniel
Luther, Anatol
Upert, Grégory
Desjonqueres, Nicolas
Brabet, Emile
Zbinden, Peter
Zerbe, Oliver
Möhle, Kerstin
Abstract
The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16 (I) and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Commissariat à l'Energie Atomique et aux Energies Alternatives (France)
Universität Zürich (Switzerland)
Inventor
Moro, Filippo
Vianello, Elisa
D'Agostino, Simone
Indiveri, Giacomo
Payvand, Melika
Abstract
The present disclosure relates to a neural network comprising a first synapse circuit (106) configured to apply a first time delay to a first input signal (READ1) using a first resistive memory element (108) and to generate a first output signal at an output of the first synapse circuit by applying a first weight to the delayed first input signal; and a second synapse circuit (106) configured to apply a second time delay, different to the first time delay, to the first input signal, or to a second input signal (READN), using a second resistive memory element (108) and to generate a second output signal at an output of the second synapse circuit by applying a second weight to the delayed second input signal.
Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.
The present invention relates to a medical system (20) for measuring visual evoked potentials (VEP) of a person, comprising a display (2) for displaying images to be observed by the person with a single eye, and an image generating module (1), the image generating module (1) being configured to cause the display (2) to display a sequence of images comprising a first image and a second image. The medical system (20) further comprises: a plurality of electrodes (3) configured to be attached to the scalp of the person and to detect EEG signals indicative of electrical activity in the brain of the person in response to observing said sequence of images displayed by the display (2), an EEG recording module (4) connected to said plurality of electrodes (3), the EEG recording module (4) being configured to record said EEG signals, and an analyzing module (8), the analyzing module (8) being configured to derive from said EEG signals recorded by the EEG recording module (4) at least one visual evoked potential (VEP).
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
The invention relates to a hydroxycarboxylic acid of the formula CH3(CH2)8 CHOH—(CH2)—CO2H or a pharmaceutically acceptable salt thereof, for use as a medicament, particularly for use in the treatment or prevention, including prevention of recurrence, of cancer, for example colorectal cancer. The invention further relates to a combination medicament for use in the treatment or the prevention of recurrence of cancer comprising a hydroxycarboxylic acid as specified herein, and another antineoplastic treatment. Further aspects of the invention relate to a method of measuring the presence of a hydroxydicarboxylic acid of the formula HO2C(CH2)7 CH2CHOH—(CH2)—CO2H, or CH3(CH2)10COOH to predict or to monitor the clinical outcome of a cancer patient, and/or to predict or monitor the response to an antineoplastic therapy or treatment with live bacteria.
C07C 53/126 - Acids containing more than four carbon atoms
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
The present invention relates to a chimeric cytokine receptor and its use in switching the polarisation of macrophages or monocytes from M2 to M1. The present invention also relates to a method for monocyte modification to selectively increase the phagocytotic activity and to modulate the polarisation of offspring macrophages.
A61B 17/42 - Gynaecological or obstetrical instruments or methods
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 90/30 - Devices for illuminating a surgical field, the devices having an interrelation with other surgical devices or with a surgical procedure
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
30.
COMPLEMENT COMPONENT 7 AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET
The present invention relates to a method for predicting the likelihood of developing, or of diagnosing, a systemic post-infection syndrome via measuring the amount of C7 in a patient sample, particularly the amount of liquid-phase (soluble) or complexed C7. The invention particularly relates to the diagnosis of long COVID. The invention further relates to a treatment or prevention of a systemic post-infection syndrome via administering to a patient an agent able to mimic or modulate the biological activity of C7.
The present invention relates to small-molecule inhibitors of the FRS2-FGFR interaction. The present invention relates the small-molecule inhibitors for use as a medicament and for use in cancer or metastasis treatment or prevention.
Rotating tissue culture insert (20, 40) for the position inside a rotatable roller bottle (100) partially filled with a liquid for the cultivation of cells comprising a scaffold (11) provided for the cultivation of cells, characterized in that the rotating tissue culture insert (20) comprises an axle body (3) and at least two protrusions extending in radial direction from the axle body (3), wherein the protrusions (4) define wheels of said rotating tissue culture insert (20) with a runway that is in contact with the surface (25) of a roller bottle (100) when the roller bottle (100) is in a lying position.
The invention relates to a method for identifying a variant of a biomolecule among a plurality of variants of the biomolecule by these steps: A) Acquiring a fluorescence intermittence signal pattern for each variant. Each of the variants is labelled with a blinking fluorophore. B) Determining a fluorescence intermittency signal characteristic for each variant. C) Labelling at least one variant of the biomolecule in a sample with the fluorophore, and acquiring its fluorescence intermittency signal. D) Determining a presence of at least one fluorescence intermittency signal characteristic as determined in step B) in the acquired fluorescence intermittency signals from the sample. E) Establishing the presence, the quantity and/or localisation, of at least one variant of the biomolecule in the sample based on the fluorescence intermittency signal characteristic.
Provided are methods of obtaining a mass culture of muscle derived muscle precursor cells (MPCs) using microcarriers as growth substrate, methods for obtaining a therapeutic efficient amount of those cells, a cell population obtained by said methods as well as compositions comprising the expanded cells and methods for preparing a medicament, for example, for use in the treatment of skeletal muscle dysfunctions.
In one aspect, the invention relates to the use of difluoromethylornithine (DFMO) in treatment of cancer. The drug is administered to a patient undergoing a dietary regimen and/or drug treatment that is designed to reduce a plasma level of proline, arginine, or both.
The present invention relates to the production of skin substitutes with a defined ratio of blood endothelial cells (BEC), to lymphatic endothelial cells (LEC), and their use in medicine.
The invention relates to protein fragments of human myelin basic protein (MBP) and nucleotide sequences encoding any thereof, for use in the treatment, diagnosis and/or prevention of multiple sclerosis (MS). More particular the invention relates to the field of antigen specific immunotherapies, such as the induction of tolerance.
The present invention relates to a bispecific antibody comprising at least a first binding domain and a second binding domain, wherein said first binding domain binds to an organic fluorophore and wherein said second binding domain binds to CD3, and to a combination thereof with a labelled binding agent that binds specifically to a target antigen, wherein the labelled binding agent is labelled with an organic fluorophore.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Disclosed herein are designed ankyrin repeat domain specifically binding to fibroblast activation protein (FAP). Such designed ankyrin repeat domains can be used in recombinant adapter molecules that are displayed on adenoviruses. Adenoviruses armed with such adapters efficiently transduce human fibroblasts and significantly broaden treatment opportunities through paracrine delivery of cargo to the tumor microenvironment (TME).
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/62 - DNA sequences coding for fusion proteins
The present invention relates to a composition for use in treating a condition of the lower gastrointestinal tract, e.g. ulcerative colitis, wherein the composition comprises: a) a carrier comprising: a1) water in an amount of more than 10% to 30% by weight of the carrier; and a2) monoacylglycerol lipid in an amount of 70% to 90% by weight of the carrier, wherein the monoacylglycerol lipid comprises monolinolein or monoolein, or combinations thereof; and b) a pharmaceutically active agent, wherein the composition forms a lipid cubic phase at a temperature of 36 °C to 39 °C. The composition is particularly suitable for rectal administration, for example, as an enema. Also disclosed is a composition, methods for preparing the compositions, and kits for making the compositions.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61P 1/06 - Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/606 - Salicylic acidDerivatives thereof having amino groups
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
41.
LIPID EMULSION WITH ANTI-INFLAMMATORY EFFECTS FOR TOTAL PARENTERAL AND ENTERAL NUTRITION
The present invention relates to a lipid emulsion for total parenteral and enteral (oral or through gastric or duodenal tubes) nutrition. The lipid emulsion has advantageous immuno-modulating, anti-inflammatory, and anti-diabetic effects. The lipid emulsion may also comprise a pharmaceutical drug, can be used as a detoxifier, or for reversing negative effects from ischemia-reperfusion injury.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 43/00 - Drugs for specific purposes, not provided for in groups
42.
ADENOVIRAL-BASED IN SITU DELIVERY OF BISPECIFIC T CELL ENGAGERS
Disclosed herein are recombinant non-oncolytic viruses, for example adenoviruses, that encode bispecific T cell engagers (BiTE's). These BiTE's can be expressed at any desired site of the human body. The non-oncolytic viruses are able to direct expression of the BiTE's in situ, i.e. directly at the site at which the BiTE's exert their action. The non-oncolytic viruses are useful in the treatment of diseases such, as cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
Provided is an injection device [1] for injection of a substance with an syringe [14] into an organism [20], comprising a holding unit [2], which is adapted to hold the syringe [14], an actuating unit [3], which is adapted for dosed injection of the injection substance and which is removably coupled to the holding [2] unit and couplable with the syringe [14] when the holding unit [2] holds the syringe [14], a needle guide [8] which is adapted to be removably couplable with an injection needle [11] and for changing the injection position of the injection needle [11]; and a connection structure [12] which connects the holding unit [2] and the needle guide [8].
A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/24 - Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
A61M 5/44 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for cooling or heating the devices or media
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical and veterinary products; dietetic substances and foodstuffs for medical or veterinary use, food for babies; dietary supplements for humans and animals; herbal supplements; homogenized food for medical use; pharmaceutical preparations in the form of tablets, capsules, sachets, drinkable solutions or suspensions; parenteral preparations; fats, oils and emulsions for medical use; biological and chemical reagents for medical or veterinary use; anti-inflammatories Infusion sets; intravenous feeding tubes; intravenous feeding bottles; intravenous catheters Provision of information on dietary supplements and nutrition; dietary and nutrition recommendation services, particularly with regard to parenteral nutrition; services provided by consultants in the medical, medicinal and pharmaceutical field; provision of information in the pharmaceutical field; medical services
45.
DIRECTED EVOLUTION OF MEMBRANE PROTEINS IN EUKARYOTIC CELLS WITH A CELL WALL
The invention relates to a method for selecting an expressed sequence from a library, comprising the following steps: Each of a plurality of eukaryotic cells comprising a cell wall comprises a nucleic acid sequence member of a library, which is expressed as a target membrane protein in said eukaryotic cells. The cell wall of the cells is permeabilized. The penneabilized cells are labeled with a ligand capable of binding to the target membrane protein. The ligand bears a detectable label. A subset of the labelled cells is selected as a function of detectable label present. Finally, an expressed nucleic acid sequence is isolated from said selection of cells in an isolation step.
The invention relates to a method, particularly a computer-implemented method for determining a fatigue value of a person, the method comprising the steps of: i) displaying of: c) a first group (1) of symbols and a second group (2) of symbols, d) a selection rule (3) associating each of the symbols of the first group (1) of symbols to one symbol of the second group (2) of symbols, ii) highlighting one symbol (11) of the first group (1) of symbols, iii) receiving a user input from the person selecting one symbol (12) of the second group (2) of symbols, iv) determining a truth value based on the selected symbol (12) of the second group (2) of symbols, wherein the truth value assumes a true value if the selected symbol (12) is selected in accordance with the selection rule (3) and wherein the truth value takes on a false value if not, wherein the highlighted symbol (11) of the first group (1) of symbols is highlighted for a predetermined time based on a statistical response time of the person, and wherein if the user input is not received within the predetermined time in step iv), the method is set forth with step v) having the truth value set to the false value, or the method is set forth with step vi), v) storing the truth value on a non-transitory memory device, vi) changing the selection rule (3), such that each of the symbols of the first group (1) of symbols is associated anew to one symbol of the second group (2) of symbols, vii) changing the highlighted symbol (11) of the first group (1) of symbols, viii) repeating steps iii) to vii) at least once and ix) based on at least some of the stored truth values, determining a fatigue value of the person.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
47.
DESALINATION AND/OR PURIFICATION DEVICE, DESALINATION AND/OR PURIFICATION CARBON MEMBRANE, AND METHOD OF DESALINATING AND/OR PURIFYING A LIQUID
King Abdullah University of Science and Technology (Saudi Arabia)
Universität Zürich (Switzerland)
Inventor
Cruz, Aluizio M.
Fratalocchi, Andrea
Bonifazi, Marcella
Mazzone, Valerio
Aegerter, Christof
Abstract
The present invention relates to a desalination and/or purification device, a desalination and/or purification carbon membrane, and a method of desalinating and/or purifying a liquid by using such a desalination and/or purification device. In various illustrative embodiments, a desalination and/or purification device is provided, the desalination and/or purification device comprising a carbon membrane body comprising a carbon surface, and a structure of microchannels and/or nanochannels at least partially permeating the carbon membrane body and ending at openings at the carbon surface, a liquid transportation structure extending at least partially through the carbon membrane body without being exposed at the carbon surface, and a condenser arranged above the carbon membrane body. The liquid transportation structure is arranged and configured to supply the structure of microchannels and/or nanochannels of the carbon membrane body with a liquid to be desalinated and/or purified and the structure of microchannels and/or nanochannels of the carbon membrane body may be an at least two-level disordered network of channels.
Present invention relates to dexmedetomidine or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of a sleep disorder in a subject, wherein dexmedetomidine or its salt is to be administered to a subject via transmucosal administration route in a dose of between 10 mcg and 120 mcg. Said dexmedetomidine or a pharmaceutically acceptable salt thereof is preferably formulated as an orodispersible tablet and is particularly useful in the treatment of insomnia.
Provided herein is a cyclic tetrapeptides including alternating α- and 3-amino acids and metal complexes thereof. The cyclic tetrapeptides are useful for coordinating a metal selected from Pb, Cd, Hg and As. Also provided herein is the use of the cyclic tetrapeptides in treating a disease, particularly metal poisoning, and the use in remediation of contaminated water and soil. Also provided herein are methods for detecting said metals in various substrates are provided.
The invention relates to a method of obtaining a variant of a T cell epitope peptide expressed in the tumour of cancer patient, wherein the variant is characterised by targeted amino acid substitutions conferring an improved capacity to stimulate CD8+ and CD4+ T cells. The invention further relates to vaccine and, pharmaceutical compositions comprising variant T cell epitope peptides and their use in treating cancer.
141313131316144)-NRN1RN2, OH, CN, halogen, NRN1RN222RSwith RN1, RN2, and RS133 alkyl, n is 0, 1, 2, 3 or 4, each R1166 alkyl, OH, ORO, COORA22, halogen, NRN1RN222RS, with RN1, RN2, RS, RA, and RO1648288 heterocycle, particularly two R156566 heterocycle, wherein the cyclo-alkyl or the heterocycle is unsubstituted or substituted with OH, COORA, ORO CN, halogen, NRN1RN222RSwith RN1, RN2, RO, RA133 alkyl, m is 0, 1, or 2, and each R21322, CN, and halogen. The compound is used as a medicament, in particular for use in treatment or prevention of cancer.
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61P 35/04 - Antineoplastic agents specific for metastasis
A61K 31/428 - Thiazoles condensed with carbocyclic rings
52.
RIBOSOMAL PROTEIN S15 IN CRISPR TRANSPOSON MEDIATED SEQUENCE ENGINEERING
The invention relates to an engineered nucleic acid targeting system for insertion of a donor polynucleotide sequence into a target DNA strand, comprising: - one or more CRISPR-associated transposase proteins or functional fragments thereof; - a Cas protein; - a guide RNA molecule capable of complexing with the Cas protein and directing sequence specific binding of the guide-Cas protein complex to a target sequence of a target DNA strand; and - a ribosomal protein S15. Any of the protein components may be provided encoded by a nucleic acid sequence. A further aspect of the invention relates to a method for inserting a cargo DNA nucleic acid sequence into a target nucleic acid DNA sequence by the system of the invention. Another aspect of the invention relates to the use of a recombinant ribosomal protein S15, in a method for inserting a donor polynucleotide sequence into a target polynucleotide sequence, said method for inserting being facilitated by a CRISPR-associated transposase system.
The present invention relates to the use of neocuproine, elesclomol, disulfiram and/or dithiocarbamate for use in treatment of cancer, optionally in combination with MAPK-pathway inhibitors in cancers carrying mutations that are recognized as MAPK-pathway activating mutations.
A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
This document provides various technical improvements for performing optical NIRS measurements using an optical sensor. The revelation concerns A) a specific measurement method, B) a specific cable design for such a sensor, C) a light shielding cover to be used with such a sensor, and D) a specific internal light shielding to be used inside the sensor. All of these aspects can be used for improving the accuracy and robustness of the optical measurements to be performed with the sensor (cf. Fig. A1).
A61B 5/1495 - Calibrating or testing in vivo probes
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
55.
LIGANDS TO GM-CSF OR GM-CSF-RECEPTOR FOR USE IN LEUKEMIA IN A PATIENT HAVING UNDERGONE ALLO-HCT
Described herein is the use of a non-agonist ligand, particularly an antibody, specifically binding to GM-CSF or one of CD116, CD131 and the GM-CSF receptor composed of CD116 and CD131 for use in treatment of leukemia in a patient having undergone allo-HCT or in treatment of other complications arising as a consequence of hematopoietic cell transplantation from an immunologically non-identical donor.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/02 - Antineoplastic agents specific for leukemia
56.
AGENTS FOR TREATMENT OF ENDOMETRIOSIS AND OTHER BENIGN GYNECOLOGICAL NEOPLASMS
The present invention relates to agents for the treatment and/or diagnosis of endometriosis and other benign gynecological neoplasms disease or disorder and also relates to agents capable of eliciting a cytotoxic response in benign gynecological neoplasms diseases or disorders.
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
The invention provides a human IL-2 (hlL-2)-specific monoclonal antibody, wherein a complex of hlL-2 and the monoclonal induces IL-2 signalling preferentially via CD25 and the trimeric IL-2R. The invention further provides a pharmaceutical composition comprising hlL-2 and said hlL-2-mAb for use treating inflammatory disease.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Disclosed herein are recombinant adenoviruses, recombinant proteins and trimeric proteins that are useful for the transduction of immune cells, such as T cells or NK cells. The present invention provides a versatile and highly specific system that is useful for numerous purposes, including the development of novel therapeutic approaches. The present invention makes use of specially designed adapter molecules that enable the specific targeting of immune cells, such as T cells or NK cells, which strongly increases transduction efficiencies, in particular for in vitro transduction of immune cells.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to an ex vivo method and means for determining the risk estimate of side effects of a drug and/or probability estimate of drug response in a subject, the method comprising collecting the mass spectra of substances present in the exhaled breath and analyzing the mass spectra using a previously trained mathematical model. The instant methods and means are particularly useful in therapeutic drug monitoring, determining the risk estimate of side effects of a drug, determining the probability estimate of drug response in the subject, and determination of subject compliance.
The present invention relates to a method for ex vivo antibody diversification, making use of a protein-RNA complex comprising an activation-induced cytidine deaminase (AID), a nuclease dead Cas9 (dCas9) or nickase Cas9 (nCas9), transcription activator VP64; and one or more single-guide RNAs (sgRNA).
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
Goods & Services
Digital notepads, electronic albums, diaries; downloadable
electronic data and publications; downloadable podcasts;
electronic newsletters; scientific instrumentation;
software, application software for mobile telephones and
tablets; software for data and document capture,
transmission, storage and indexing. Collection of psychological data on development for
scientific purposes; collection, systematization and
recording of data in a computer database. Education; training, sporting and cultural activities;
preparation and hosting of conferences, congresses,
seminars, symposiums, lectures, lessons and training
courses; online publication of electronic books, newsletters
and newspapers.
62.
VIRAL VECTORS EXPRESSING THERAPEUTIC PROTEINS SPECIFICALLY IN MYELOID CELLS AND MICROGLIA
The present invention provides novel viral vectors for use in human therapy, particularly for use in in the treatment of a disease or disorder which has its origin in the brain or is brain based, particularly a PGRN-associated neurodegenerative disease or disorder including frontotemporal degenerative disease or disorder such as Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The invention also provides viral vectors for use in the treatment of brain tumors, particularly brain tumors selected from the group consisting of glioblastoma, glioma, ganglioneuroblastoma, astrocytoma, oligodendroglioma, PNET (primitive neuroectodermal), medulloblastoma, CNS lymphoma, and neuroblastoma, or any other CNS tumor and further in the treatment of brain metastasis, originating from any forms of breast, lung, colon, testicular, renal carcinomas and melanoma, or any other solid tumor, and any hematologic tumor, comprising all forms of leukemia and lymphomas. Further, the viral vectors may be used in the treatment of autoimmune diseases, inflammatory diseases and/or allergic diseases.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to a method for transducing a target cell, the method comprising the step of contacting a target cell with a retroviral vector and a compound capable of enhancing transduction efficiency or a combination of such compounds, wherein the target cell is pre- and/or co-stimulated by pre- and/or co-incubation with said transduction enhancing compound or a combination of transduction enhancing compounds prior to and/or during contacting the target cell with the retroviral vector.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
64.
STABILIZING N-CAP SEQUENCES FOR ARMADILLO REPEAT PROTEINS
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
65.
SMALL-MOLECULE INHIBITORS OF THE FRS2-FGFR INTERACTION AND THEIR USE IN MEDICINE, IN THE PREVENTION AND TREATMENT OF CANCER
The present invention relates to small-molecule inhibitors of the FRS2-FGFR interaction. The present invention relates the small-molecule inhibitors for use as a medicament and for use in cancer or metastasis treatment or prevention.
The present invention relates to small-molecule inhibitors of the FRS2-FGFR interaction. The present invention relates the small-molecule inhibitors for use as a medicament and for use in cancer treatment or prevention.
The present invention relates to a contrast agent suitable for ex vivo imaging, particularly of vascular structures and renal tubular structures, and a method for ex vivo imaging. The contrast agent is a polymer comprising monomers M. The monomer comprises a backbone having 2 to 6 elements, wherein at least one element is —CH(R)— or —N(R)—. R is a moiety -E-H, -L-(NH2)m or a moiety of formula 1, with E, L, R1 and R2 being defined as described in the present specification. The monomer comprises at least one —I to allow detection via X-ray and at least one —NH2 to allow crosslinking. Furthermore, the monomer comprises polar functional groups that contribute to water solubility. To avoid extravasation and glomerular filtration, the polymers are pre-crosslinked before the vasculature of a tissue, an organ or whole animal is perfused. After perfusion, the pre-crosslinked contrast agent is further crosslinked to be retained within the tissue, organ or animal permanently.
C07C 233/55 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
68.
CONTAINER FOR THE STORAGE AND MRI ANALYSIS OF BRAINS IN PATHOLOGY
The present invention relates to a container (1) for storing a human or animal brain (2), comprising: a plurality of layers, the layers (10, 20, 21, 30) being configured to be stacked on top of one another, wherein said plurality of layers comprises a bottom layer (10), a top layer (30) and optionally also intermediary layers (20, 21) configured to be arranged between the bottom and the top layer (10, 30), and wherein the layers (10, 20, 21, 30) form a cavity (3) for accommodating the brain (2) when being stacked on top of one another. Furthermore, a coordinate system is integrated into the container (1) and the container (1) can serve as a tool for correlating MRI and histology.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 16/00 - Devices specially adapted for vivisection or autopsy
Disclosed herein is an adenoviral vector system utilizing DARPin adapters. The system is highly effective, safe and able to deliver DNA in a cell-specific manner. It is demonstrated that the system is unexpectedly versatile, and can be used in conjunction with protein scaffolds, bioactive peptides and small molecules. This makes the system useful for numerous purposes, including the use of the system for therapeutic and diagnostic purposes.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C12N 15/62 - DNA sequences coding for fusion proteins
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
The present invention relates to the field of assessment of the health status, particular with regard to prostate cancer risk, by measurement of certain proteins in human samples, in particular in human urine.
Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.
The present invention relates to the field of assessment of the health status, particular with regard to prostate cancer risk, by measurement of certain proteins in human samples, in particular in human urine.
Computer system (100) and method for index creation in a streaming database (130) with medical state parameters of different types associated with a plurality of patients (10) is provided to allow near-real-time access to medical state parameters reflecting medical states of patients. A message broker (110) receives messages in one or more incoming data streams (30). The messages include records with current measured medical state parameter values (11-1) of patients. A stream processor (120) processes incoming messages with a plurality of parameter augmentation algorithms (PAA1 to PAAn) wherein each parameter augmentation algorithm is adapted to derive additional computed medical state parameter values for the respective patient. Records with the computed values are then inserted via generated messages (mg*) into any incoming data stream. A data handler (140) can create persisted patient-signal specific stream data tables for yet unknown combinations of patient identifier and signal identifier in the streaming database (130), and can further create a block range index for the time information of said persisted stream data table. Records contained in the received and generated messages (m*, mg*) are then written into respective persisted patient-signal specific stream data tables (SDT-P2-S1 to SDT-P2-Sn) of the streaming database (130), and the respective block range indexes are updated accordingly upon record insertion.
The invention relates to a device to be used for closing a tissue opening in a tissue. In particular, the present invention relates to a device used for a closing an opening in a membrane such as a fetal membrane by stitching in a minimally invasive procedure.
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
75.
SMALL-MOLECULE INHIBITORS OF THE FRS2-FGFR INTERACTION
The present invention relates to small-molecule inhibitors of the FRS2-FGFR interaction. The present invention relates the small-molecule inhibitors for use as a medicament and for use in cancer or metastasis treatment or prevention.
The invention relates to a method for providing a multiplexed RNA expression plasmid, comprising the steps of providing a plasmid backbone fragment comprising a 5' backbone end and a 3' backbone end; providing plurality of n insert fragments, wherein each insert comprises a sequence encoding a transcribed RNA sequence, and one of said insert fragments additionally encodes an insert selection marker under control of a promoter operable in a host cell. The fragments are inserted into the backbone by Gibson assembly. The product of the Gibson assembly are transformed into bacterial host cells and the ligated plasmid products are isolated. The invention further relates to a library made by the method described in the invention.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
77.
SMALL MOLECULE BINDERS OF THE ONCOGENIC FUSION TRANSCRIPTION FACTOR PAX3-FOXO1
The present disclosure provides compounds having the general formula P-L-U, or pharmaceutically acceptable salts thereof, wherein P is a FOXO1 fusion protein binding moiety, L is a bivalent linker, and U is an ubiquitin ligase binding moiety. Also provided are pharmaceutical compositions containing such compounds and methods of using such compounds.
A61K 31/401 - ProlineDerivatives thereof, e.g. captopril
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The present invention relates to a non-agonist ligand of ARTC1, which inhibits the ADP-ribosyltransferase activity of ARTC1, or an inhibitor nucleic acid sequence capable of downregulating or inhibiting expression of a target nucleic acid sequence encoding ARTC1, for use in prevention or treatment of cancer. The invention also relates to a method for diagnosis of cancer.
The present disclosure provides compounds having the general formula P-L-U, or pharmaceutically acceptable salts thereof, wherein P is a FOXO1 fusion protein binding moiety, L is a bivalent linker, and U is an ubiquitin ligase binding moiety. Also provided are pharmaceutical compositions containing such compounds and methods of using such compounds.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A delivery system (10, 110) is provided for delivering and deploying an implantable balloon-based occlusion device (20) including an inflatable balloon (22). The delivery system (10, 110) includes a delivery handle (11), which includes a fluid-retaining chamber (41, 141); a plunger, which is slidingly disposed in the fluid-retaining chamber (41, 141); and a proximal rotatable user-control knob (31). A fluid-conveyance lumen catheter (18) defines a catheter fluid-conveyance lumen (19) in fluid communication with the fluid-retaining chamber (41, 141) and the inflatable balloon (22). A catheter lumen shaft (26) is in reversible connection with the balloon-based occlusion device (20), longitudinally slidable with respect to the delivery handle (11). The delivery handle (11) is configured such that rotation of the proximal rotatable user-control knob (31) in a first rotational direction concurrently (a) expels at least some of the fluid from the fluid-retaining chamber (41, 141) into the inflatable balloon (22), via the catheter fluid-conveyance lumen (19), and (b) shortens a length of the balloon-based occlusion device (20) by proximally pulling the catheter lumen shaft (26). Other embodiments are also described.
A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
The present invention relates to an immersion microscope objective (10) for inspecting a sample (S) in an immersion medium (M), comprising: at least one concave minor (3), at least one optical element (1) comprising an aspherical surface (2) facing the at least one concave minor (3), and an internal space (4) arranged between the at least one concave minor (3) and said aspherical surface (2), said internal space (4) being configured to be filled with an immersion medium (M) such that the immersion medium (M) contacts the at least one concave minor (3) and the aspherical surface (2). According to the present invention, the aspherical interface (2) is shaped such that the working distance (7) of the immersion microscope objective (10) varies by less than 1% when the refractive index n of said immersion medium (M) is increased or decreased by at least 0.025.
The invention relates to a method for producing a dental prosthesis for use in dental technology which allows a dental model to be produced on the basis of digital patient data such that it can be automatically positioned in the correct position in a physical articulator. The invention further relates to dental models produced in this way, to devices for taring articulators and to computer programs specifically developed for the method.
A61C 11/08 - Dental articulators, i.e. for simulating movement of the temporo-mandibular jointsArticulation forms or mouldings with means to secure dental casts to articulator
A61C 13/34 - Making or working of models, e.g. preliminary castings, trial denturesDowel pins
B33Y 80/00 - Products made by additive manufacturing
A61C 19/05 - Measuring instruments specially adapted for dentistry for determining occlusion
83.
TIP LIGHT LARYNGOSCOPE FOR TRANS-TISSUE ILLUMINATION
A tip light laryngoscope adapted for the trans-tissue illumination during insertion of the laryngoscope, preferably in the mucosal fold between tongue base and the epiglottis referred to as the vallecula, includes a handle and a blade with a tip at the end of the blade and a distal light source at the tip to enlighten the environment in front of the tip. The tip light laryngoscope is designed to make direct contact with the mucosa.
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
84.
MODULAR NEURAL SENSING SYSTEM FOR PREDICTING PHYSICOCHEMICAL PROPERTIES
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (Spain)
Inventor
Margarit Taulé, Josep Maria
Liu, Shih-Chii
Jiménez Jorquera, Cecilia
Abstract
A modular artificial neural sensing system includes a hierarchical network of neural sensing units including a neuromimetic sensor array of artificial sensory synapses and sensory neurons for receiving physicochemical sensed signals and for outputting sensor output signals. An artificial neural network processor is adapted for processing the sensor output signals and includes processor neurons interconnected by processor synapses forming first connections and second connections. The processor outputs processor output signals. A first sensor interface feeds processed or unprocessed sensed signals into the processor. A second sensor interface receives output predicted signals from other neural sensing units and feeds processed or unprocessed output predicted signals into the processor. A signal decoder decodes the processor output signals and outputs decoder output signals. An error feedback module receives the decoder output signals and teaching signals for generating error signals depending on a difference between teaching signals and decoder output signals.
The invention provides a bacterial composition comprising, or consisting of, one or more of the genera of bacteria selected from Anaerostipes, and/or Roseburia, for treatment, or for prevention of recurrence, of cancer. In another aspect, the invention relates to a combination medicament for use in the treatment or the prevention of recurrence of cancer comprising a bacterial composition as specified herein and an antineoplastic treatment, particularly a combination medicament comprising a bacterial composition and a cancer chemotherapy drug, or a bacterial composition as provided herein and a cancer immunotherapy drug.
A computer-implemented method is used to adapt a first artificial neural network for data classification tasks. The first artificial neural network is characterized by a first number of first weight parameters, and includes a set of first network layers. The method includes freezing at least some of the first weight parameters of the first neural network to obtain frozen first weight parameters and duplicating the frozen first weight parameters to obtain duplicated first weight parameters. A second artificial neural network is applied to the duplicated first weight parameters to obtain modulated first weight parameters. The second artificial neural network is characterized by a second number of second weight parameters, the second number being smaller than the first number. The frozen first weight parameters are replaced in the first neural network with the modulated first weight parameters to obtain a modulated first artificial neural network adapted for a data classification task.
The invention relates to a computer-implemented method for training an agent of a reinforcement learning method for determining a surgery plan, particularly a surgical access and manipulation of a tissue, the method comprising the steps of: a) generating (200) a three-dimensional analytical representation (2) corresponding to a parametrized segmentation of a tissue portion, wherein the segmentation of the tissue portion subdivides the tissue portion in kinds of tissue of the tissue portion, b) generating (300) from the analytical representation (2) a corresponding state space configured and designed for the reinforcement learning method to train the agent (1), wherein the state space comprises a plurality of states (s), wherein each state (s) comprises an information on its associated location in the tissue portion and an information indicative of at least the kind of tissue in the tissue portion it represents, c) performing a training (400) of the agent (1) in the analytical representation (2) and the state space by means of the reinforced learning method to obtain a trained agent, wherein the training is performed by repeating step b) several times, wherein for at least some repetitions of step b) the analytical representation (2) is varied by adjusting the parametrized segmentation by way of adjusting at least one parameter of the parametrized segmentation to obtain an analytical representation (2) of a varied tissue portion.
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
88.
IL-1 TARGETING AGENTS FOR TREATMENT OF PITIYRIASIS RUBRA PILARIS
The invention relates to the use of an agent for use in treatment of Pityriasis rubra pilaris (PRP). The agent is selected from a ligand capable of specifically binding to, and inhibiting the physiological activity of, interleukin-1, and a nucleic acid agent capable of down-regulating or inhibiting the physiological activity of interleukin-1. In particular embodiments, the invention relates to the use of anakinra in treatment of PRP, particularly therapy-refractive PRP.
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (USA)
Inventor
Grossniklaus, Ueli
Chumak, Nina
Ozias-Akins, Peggy
Conner, Joann
Abstract
The present invention relates to a transgenic apomictic plant. The present invention further relates to a method of the production of an apomictic plant, and the seed of the transgenic apomictic plant. The instant means and methods are particularly useful in maintaining heterozygosity in hybrid plants and in the production of hybrid seeds.
The invention is related to a device (1) for receiving a biological sample (3) wherein the device (1) comprises a plurality of wells (10) wherein each well (10) comprises an inner surface (14) facing a volume (60) for receiving a biological sample (3). The inner surface (14) comprises a top section (20) and a bottom section (30). The top section (20) and the bottom section (30) are connected via a circumferential step (40). The circumferential step (40) forms a stop for a tip of a pipette (70).
BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (Switzerland)
UNIVERSITAT ZURICH (Switzerland)
Inventor
Obrecht, Daniel
Luther, Anatol
Upert, Gregory
Desjonqueres, Nicolas
Brabet, Emile
Zbinden, Peter
Jung, Francoise
Zerbe, Oliver
Mohle, Kerstin
Abstract
The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16 (I) and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16 (I) and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
93.
NEUROCOMPUTATIONAL ELECTROCHEMICAL SENSING DEVICE FOR PREDICTING PROPERTIES OF A SUBSTANCE
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (Spain)
Inventor
Margarit Taulé, Josep Maria
Liu, Shih-Chii
Jiménez Jorquera, Cecilia
Abstract
A neurocomputational electrochemical sensing device (1) is proposed for predicting properties of a substance. The device (1) comprises: a plurality of electrochemical sensors constituting a sensor array (3), the sensors being sensitive to sensed attributes advantageous to predict a set of properties of interest of the substance, each sensor being configured to output a sensor output signal indicative of a sensor response of the respective sensor to measurable changes in the sensed attributes of the substance; a readout circuit (5) for biasing the sensors and for conditioning the sensor output signals into readout circuit output signals to facilitate further processing of the sensor responses; and an artificial neural network processor (7) for processing the readout circuit output signals, the processor (7) comprising neurons interconnected by synapses, the processor (7) being configured to output a set of processor output signals whose signal values are indicative of the properties to predict. The sensor array (3) comprises first electrochemical sensors selective to properties correlated with the desired properties to predict, and second electrochemical sensors sensitive primarily to the main interferents of the substance. The neurons and/or the synapses are configured to be trained to compensate for sensor drift and/or cross-sensitivities upon generating the processor output signals.
G01N 27/27 - Association of two or more measuring systems or cells, each measuring a different parameter, where the measurement results may be either used independently, the systems or cells being physically associated, or combined to produce a value for a further parameter
94.
TREATMENT AND/OR PREVENTION OF DIGESTIVE DISORDER BY A BACTERIAL COMPOSITION OF PROPIONIBACTERIUM FREUDENREICHII AND BIFIDOBACTERIUM LONGUM
The novel invention is based, at least in part, on the surprising finding that the combination of bacterial strains comprising P. freudenreichii JS27 and B. longum subsp. infantis, particularly B. longum subsp. infantis TPY12-1 can be used in medicine and/or as a food supplement when grown simultaneously. As such and as shown in the description and appended examples, growth and viability of bacterial strains possessing synergistic behavior can be enhanced in the human gut and thus can increase bioavailability as compared with alternative combinations of bacteria.
The present invention relates to a method for diagnosing Sézary syndrome or mycosis fungoides in a subject. The present invention further relates to a method for determining the frequency of Sézary signature cells and/or mycosis fungoides cells in a sample. Further, the present invention relates to a computer-implemented method comprising a classifier algorithm to determine the frequency of Sézary signature cells and/or mycosis fungoides cells. In addition the present invention relates to a panel of biomarkers that can be used for the diagnosis of Sézary syndrome or mycosis fungoides.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
The invention relates to a method to indicate the clinical outcome of a cancer patient by labelling a cancer sample with labelled molecular probes, assaying the expression of a plurality of biomolecules at the resolution of a single cell and assigning a cellular identity (CI) to each single cell in the sample based on their expression pattern; then assigning a single cell pathology (SCP) patient group according to the proportion of each CI the sample contains.
The invention relates to a method to indicate the clinical outcome of a cancer patient by labelling a cancer sample with labelled molecular probes, assaying the expression of a plurality of biomolecules at the resolution of a single cell and assigning a cellular identity (CI) to each single cell in the sample based on their expression pattern; then assigning a single cell pathology (SCP) patient group according to the proportion of each CI the sample contains.
The invention in other aspects relates to methods of treatment of a patient with anticancer drugs according to the patient's assignment to particular SCPs. Alternatively, this aspect may be formulated as the provision of certain drugs for treatment of cancer in patients characterized by tumours assigned to certain SCPs.
The disclosure relates to the field of multiple sclerosis (MS) stratification by analyzing the body fluid of an MS patient for CD27- Thl CD4+ cells in a body fluid, such as blood or CSF. The invention also relates to the field of antigen specific immunotherapies for MS, such as the induction of tolerance involving e.g. GDP-L-fucose synthase for responders.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to an isolated human hematopoietic stem cell or progenitor cell, transduced with a lentiviral vector which comprises a coding nucleic acid sequence encoding a functional variant of a polypeptide selected from gp9lphox, p22phox, p40phox, p47phox, p67phox and Rac2; under transcriptional control of a promoter sequence that comprises or essentially consists of the miR223 promoter sequence (SEQ ID NO 01).
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
99.
N6-ADENOSINE-METHYLTRANSFERASE INHIBITORS IN CANCER TREATMENT
The present invention relates to N6-adenosine-methyltransferase inhibitors and to dual N6-adenosine-methyltransferase E3 ligase binders in cancer treatment.
An occlusion device (210) is provided for occluding a left atrial appendage (LAA), including a compliant balloon (230) defining a fluid-tight balloon chamber (232), and an actuating shaft (234), which is disposed at least partially within the balloon chamber (232) for setting a distance between distal and proximal end portions (236, 238) of the balloon (230). A proximal LAA-orifice cover (70) includes a frame (72) and a covering (74) fixed to the frame (72). An orifice-support stent (290) is fixed to and extends distally from the proximal LAA-orifice cover (70), and is generally cylindrical when in a radially-expanded state. Other embodiments are also described.
A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
A61B 17/00 - Surgical instruments, devices or methods
